Hikma Pharmaceuticals PLC (HIK.L)
- Previous Close
1,854.00 - Open
1,861.00 - Bid --
- Ask --
- Day's Range
1,861.00 - 1,920.00 - 52 Week Range
1,711.00 - 2,222.00 - Volume
369,890 - Avg. Volume
627,527 - Market Cap (intraday)
4.245B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
28.13 - EPS (TTM)
0.68 - Earnings Date Feb 22, 2024
- Forward Dividend & Yield 0.57 (2.98%)
- Ex-Dividend Date Mar 21, 2024
- 1y Target Est
25.93
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
www.hikma.com9,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HIK.L
Performance Overview: HIK.L
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HIK.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HIK.L
Valuation Measures
Market Cap
4.24B
Enterprise Value
5.01B
Trailing P/E
28.15
Forward P/E
11.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.85
Price/Book (mrq)
2.42
Enterprise Value/Revenue
1.74
Enterprise Value/EBITDA
9.08
Financial Highlights
Profitability and Income Statement
Profit Margin
6.61%
Return on Assets (ttm)
8.46%
Return on Equity (ttm)
8.81%
Revenue (ttm)
2.88B
Net Income Avi to Common (ttm)
190M
Diluted EPS (ttm)
0.68
Balance Sheet and Cash Flow
Total Cash (mrq)
229M
Total Debt/Equity (mrq)
53.92%
Levered Free Cash Flow (ttm)
445.25M
Research Analysis: HIK.L
Company Insights: HIK.L
HIK.L does not have Company Insights